Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Busy address KBO
81 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2025
BeOne Medicines Belgium from Brussel, company number BE1001115521, closed financial year 2025 with a result of € 377,994 after tax. For that financial year BeOne Medicines Belgium recorded a gross margin of € 4.6 million and equity of € 651,796. Compared with financial year 2024, the result moved from € 223,802 to € 377,994. Profitable, and profit is growing. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on July 23, 2026.
€ 651,796
▲ 138% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 377,994
▲ 69% vs 2024
Profit after tax over the fiscal year.
€ 1.5 million
▲ 128% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 601,796.
People and assets in 2025
12.5
▲ 1.6 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 4 million
▲ 97% vs 2024
€ 323,800 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 437,586
▼ 45% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 1.3 million
▲ 108% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|
| Gross margin | € 2,422,906 | € 4,600,300 | ▲ 90% |
| Profit after taxes | € 223,802 | € 377,994 | ▲ 69% |
| Equity | € 273,802 | € 651,796 | ▲ 138% |
| Total debts | € 1,491,797 | € 1,780,818 | ▲ 19% |
| Cash | € 647,361 | € 1,475,748 | ▲ 128% |
| Retained profit | € 223,802 | € 601,796 | ▲ 169% |
| Balance sheet total | € 1,765,599 | € 2,432,614 | ▲ 38% |
| Employees (FTE) | 10.9 | 12.5 | ▲ 1.6 |
Key figures of BeOne Medicines Belgium, fiscal years 2024 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to BeOne Medicines Belgium?
What happened at BeOne Medicines Belgium in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 377,994 (▲ 69% vs 2024). Source: NBB ↗
- New establishment in Brussel. KBO
- Pierre MALPOT became a director. NBB
- Sandro DE ANGELIS became a director. NBB
- Carole Coudray became a director. NBB
- Start of the company according to the CBE. KBO
In short
From € 223,802 profit in 2024 to € 377,994 profit in 2025.
Paid € 314,205 in corporate taxes since 2024.
Best year ever: 2025, with € 377,994 profit.
On average € 368,000 of value added per employee in 2025.
A new publication or filing at BeOne Medicines Belgium? We notify you, reason included.
Follow BeOne Medicines BelgiumDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind BeOne Medicines Belgium are Pierre MALPOT, Sandro DE ANGELIS and Carole Coudray.
Directors
According to the 2025 annual accounts
Pierre MALPOT
Director
since 2023
Sandro DE ANGELIS
Director
since 2023
Carole Coudray
Director
since 2023
Establishments
Establishment units
Physical locations of this company
Wolstraat 70
1000 Brussel
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 81 companies are registered at this address.
All companies at this address →finance&invest.brussels
€ 20,250 revenue · 2025
IMMOWEB
€ 61.3 million revenue · 2025
KORN FERRY (BE)
€ 23.5 million revenue · 2025
BRUXELLES INFRASTRUCTURE FINANCE - BRUSSEL INFRASTUCTUUR FINANCIERING
€ 717,081 revenue · 2025
BRUSTART BY FINANCE&INVEST.BRUSSELS
+76 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 1001.115.521
- VAT number
- BE 1001.115.521
- Registered office
- Wolstraat 70, 1000 Brussel
- Names & denominations
- BeOne Medicines Belgium
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 12 October 2023
- Peppol
- Active · Active since 19 Nov 2025
- Activities · NACE
Groothandel in farmaceutische en medische artikelen